KSWA
SUPN icon

Kathleen S. Wright Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

Kathleen S. Wright Associates’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$22.7K Hold
475
– – 0.01% 184
2025
Q2 		$15K Hold
475
– – 0.01% 202
2025
Q1 		$15.6K Hold
475
– – 0.01% 202
2024
Q4 		$17.2K Hold
475
– – 0.01% 202
2024
Q3 		$14.8K Buy
+475
New +$14.8K 0.01% 230

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kathleen S. Wright Associates's SUPN Position: Q3 2025 in Review

Kathleen S. Wright Associates held its Supernus Pharmaceuticals (SUPN) position steady in Q3 2025 at 475 shares worth $22.7K. The position accounts for 0.01% of the portfolio, ranked #184.

Kathleen S. Wright Associates first reported a position in SUPN in Q3 2024 and has held it in 5 quarters since. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Kathleen S. Wright Associates held 475 shares of Supernus Pharmaceuticals worth $22.7K as of Q3 2025.
  • Kathleen S. Wright Associates left its Supernus Pharmaceuticals share count unchanged in Q3 2025.
  • Supernus Pharmaceuticals made up 0.01% of Kathleen S. Wright Associates's portfolio in Q3 2025, its #184 holding.
  • Kathleen S. Wright Associates first reported a position in Supernus Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Kathleen S. Wright Associates's 13F filing for Q3 2025, filed 10 Oct 2025.